Show simple item record

dc.contributor.authorMacFarlane, I A
dc.contributor.authorBeardwell, Colin G
dc.contributor.authorShalet, Stephen M
dc.contributor.authorAinslie, Gill
dc.contributor.authorRankin, Elaine M
dc.date.accessioned2011-05-31T14:36:57Z
dc.date.available2011-05-31T14:36:57Z
dc.date.issued1982-04
dc.identifier.citationGlycoprotein hormone alpha-subunit secretion in patients with pituitary adenomas: influence of TRH, LRH and bromocriptine. 1982, 99 (4):487-92 Acta Endocrinol.en
dc.identifier.issn0001-5598
dc.identifier.pmid6803489
dc.identifier.doi10.1530/acta.0.0990487
dc.identifier.urihttp://hdl.handle.net/10541/132365
dc.description.abstractTwelve patients with pituitary adenomas and increased serum concentration of the glycoprotein hormone alpha-subunit were studied. Eight patients were acromegalic and one had a FSH producing tumour. The adenomas in 9 patients had undergone subtotal operative removal and/or external irradiation but no patient was studied within 3 months of these treatments. Many of the acromegalic patients, with moderately elevated alpha-levels, showed marked increases in alpha-concentration after TRH and/or LRH, compared with controls. The non-acromegalic patients, with the highest alpha-levels, showed poor responses to releasing hormones. These results suggest that excessive alpha-subunit secretion in acromegalic patients is often under hypothalamic control whereas in non-acromegalic patients it is often autonomous. Seven patients, 4 with acromegaly, were then given oral bromocriptine, 5 mg over 3 h. There was a significant fall in log mean alpha-level at 4 and 5 h (P less than 0.02). Six patients took bromocriptine for 1--2 months. Log mean alpha-concentration was significantly reduced at the end of treatment (P less than 0.02) and then recovered to basal levels after stopping treatment for one week. alpha-Subunit hypersecretion in some patients with pituitary adenomas is therefore modulated by dopaminergic control mechanisms.
dc.language.isoenen
dc.subject.meshAcromegaly
dc.subject.meshAdenoma
dc.subject.meshBromocriptine
dc.subject.meshFemale
dc.subject.meshGlycoproteins
dc.subject.meshGonadotropin-Releasing Hormone
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshPituitary Neoplasms
dc.subject.meshReceptors, Dopamine
dc.subject.meshThyrotropin-Releasing Hormone
dc.titleGlycoprotein hormone alpha-subunit secretion in patients with pituitary adenomas: influence of TRH, LRH and bromocriptine.en
dc.typeArticleen
dc.identifier.journalActa Endocrinologicaen
html.description.abstractTwelve patients with pituitary adenomas and increased serum concentration of the glycoprotein hormone alpha-subunit were studied. Eight patients were acromegalic and one had a FSH producing tumour. The adenomas in 9 patients had undergone subtotal operative removal and/or external irradiation but no patient was studied within 3 months of these treatments. Many of the acromegalic patients, with moderately elevated alpha-levels, showed marked increases in alpha-concentration after TRH and/or LRH, compared with controls. The non-acromegalic patients, with the highest alpha-levels, showed poor responses to releasing hormones. These results suggest that excessive alpha-subunit secretion in acromegalic patients is often under hypothalamic control whereas in non-acromegalic patients it is often autonomous. Seven patients, 4 with acromegaly, were then given oral bromocriptine, 5 mg over 3 h. There was a significant fall in log mean alpha-level at 4 and 5 h (P less than 0.02). Six patients took bromocriptine for 1--2 months. Log mean alpha-concentration was significantly reduced at the end of treatment (P less than 0.02) and then recovered to basal levels after stopping treatment for one week. alpha-Subunit hypersecretion in some patients with pituitary adenomas is therefore modulated by dopaminergic control mechanisms.


This item appears in the following Collection(s)

Show simple item record